Memantine Grindeks (Memantine Hydrochloride)

Memantine works by binding to the ion channel of the N‑methyl‑D‑aspartate (NMDA) receptor as a non‑competitive antagonist. This blocks excessive calcium influx that occurs during prolonged glutamate stimulation, reducing excitotoxic neuronal injury while allowing normal synaptic activity, thereby supporting neuronal function in Alzheimer’s disease.

The dosing regimen for memantine is individualized by the prescribing physician based on the patient’s clinical condition, renal function, and tolerability. Typical titration starts with a low dose that is gradually increased to the target maintenance dose, but the exact schedule should be determined by a qualified healthcare professional.

Safety data for memantine in pregnancy and lactation are limited. It is classified as a pregnancy category with unknown risk, and the drug is excreted in breast milk. Use during pregnancy or breastfeeding should only occur when the potential benefits outweigh the possible risks, and under medical supervision.

To place an order, submit an inquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Memantine belongs to the NMDA receptor antagonist class, whereas other approved agents such as donepezil, rivastigmine, and galantamine are acetylcholinesterase inhibitors. Memantine targets glutamatergic excitotoxicity, offering a complementary mechanism that can be used alone or in combination with acetylcholinesterase inhibitors for broader symptom control.

Memantine Grindeks should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency throughout its shelf life.

The medication is taken orally, usually as a tablet, with or without food. Patients should follow the dosing schedule prescribed by their healthcare provider, swallow the tablet whole, and avoid crushing or chewing unless specifically instructed.

Although uncommon, serious adverse reactions can include seizures, severe hypertension, hepatic injury, and psychotic symptoms such as hallucinations or delusions. Patients should be monitored closely for these events, and any sudden or severe symptoms should prompt immediate medical evaluation.

Memantine is contraindicated in patients with known hypersensitivity to memantine hydrochloride or any of the tablet’s excipients. Caution is also advised for individuals with severe renal impairment, uncontrolled hypertension, or a history of seizures, and it should be avoided in combination with other NMDA antagonists unless directed by a physician.